自然化合物的分子对接,以潜在抑制AhRR
Deborah Giordano1, Angelo Facchiano1, Stefania Moccia1
1National Research Council, Institute of Food Sciences, 83100 Avellino, Italy.
Foods (Basel, Switzerland)
|May 27, 2023
概括
像β-胡卜素和酸这样的天然化合物可以抑制烯碳水化合物受体 (AhR). 这一发现通过计算建模和体外试验验证,为准与AhR相关的疾病提供了新的途径.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 基碳化合物受体 (AhR) 是一种转录因子,参与细胞过程和癌症和炎症等疾病.
- 激活AhR涉及与ARNT的异构化和与外源生物反应元素 (XREs) 的结合.
研究的目的:
- 研究天然化合物对AhR的潜在抑制活性.
- 使用计算方法识别AhR抑制的新型结合口袋.
主要方法:
- 构建一个人类AhR模型 (bHLH,PAS A,PAS B域).
- 盲目和集中对接模拟,以确定潜在的绑定位置.
- 使用HepG2细胞进行体外验证,以评估[a]皮林 (BaP) 诱导的AhR激活的抑制.
主要成果:
- 对接模拟揭示了超出正规PAS B域的新型绑定口袋.
- 这些口袋可能会阻碍AhR:ARNT异体化,这对AhR功能至关重要.
- β-胡卜素和酸证明了在HepG2细胞中抑制BaP诱导的AhR激活.
结论:
- 计算方法成功地确定了潜在的AhR抑制剂.
- 贝塔胡卜素和基酸作为天然AhR调节剂具有前景.
- 已识别的结合口袋为开发抑制AhR的药物提供了新的目标.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.4K
05:08Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
Published on: July 8, 2025
154
相关概念视频
Structure-Activity Relationships and Drug Design
801
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
801
Drug-Receptor Interactions
5.4K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.4K
Drug-Receptor Bonds
3.0K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
3.0K
Targets for Drug Action: Overview
6.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.5K
Principles of Drug Action
6.2K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
6.2K
The Two-State Receptor Model
2.0K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
2.0K
